deltatrials
Recruiting NA INTERVENTIONAL 2-arm NCT07235007

Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma (BRAVE)

Survival Impact of Repeated Endobiliary Radiofrequency Ablation in Patients Undergoing Durvalumab Plus Gemcitabine and Cisplatin for Extrahepatic Cholangiocarcinoma: An International Multicenter Randomized Controlled Trial (BRAVE Trial)

Sponsor: Aichi Medical University

Conditions Extrahepatic Cholangiocarcinoma
Interventions Endobiliary Radiofrequency Ablation (EB-RFA) Plastic Biliary Stent
Updated 2 times since 2025 Last updated: Jan 11, 2026 Started: Nov 20, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Extrahepatic Cholangiocarcinoma and is currently actively recruiting participants. Aichi Medical University leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshotRecruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting NA

  2. Dec 2025 — Feb 2026 [monthly]

    Recruiting NA

    First recorded

Nov 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aichi Medical University
Data source: Aichi Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations